تحميل...
Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention
IMPORTANCE: Recently, 12 randomized clinical trials (RCTs) have demonstrated the efficacy of novel therapies for mainly secondary prevention of atherosclerotic cardiovascular disease. However, given the potential overlapping eligibility of the RCTs, along with the cost of the new therapies, there ar...
محفوظ في:
| الحاوية / القاعدة: | JAMA Cardiol |
|---|---|
| المؤلفون الرئيسيون: | , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
American Medical Association
2020
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6990962/ https://ncbi.nlm.nih.gov/pubmed/31895459 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2019.4759 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|